News Releases

Date Title and Summary Additional Formats
Toggle Summary Avid Bioservices to Present at NobleCon14
TUSTIN, Calif. , Jan. 23, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that its president and chief
View HTML
Toggle Summary Peregrine Pharmaceuticals Announces Name Change to Avid Bioservices as Part of Transition to Dedicated Contract Development and Manufacturing Organization (CDMO)
Company Adopts "CDMO" as New Nasdaq Ticker Symbol; Will Initiate Trading Under New Ticker on January 8, 2018
View HTML
Toggle Summary Peregrine Pharmaceuticals to Present at Biotech Showcase 2018
TUSTIN, Calif. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company committed to improving patient lives by manufacturing and delivering high quality biologics, today announced that its president and chief executive officer, Roger J.
View HTML
Toggle Summary Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D., as President and Chief Executive Officer
TUSTIN, Calif. , Dec. 26, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company committed to improving patient lives by manufacturing and delivering high quality biologics, today announced the appointment of Roger J.
View HTML
Toggle Summary Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent Developments
-- Avid Bioservices Records Revenues of $12.8 Million in the Second Quarter of FY2018 --                -- Transition to a Dedicated CDMO Business Nearing Completion -- TUSTIN, Calif. , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc.
View HTML
Toggle Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock
TUSTIN, Calif. , Dec. 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").
View HTML
Toggle Summary Peregrine Pharmaceuticals to Report Financial Results for Second Quarter of Fiscal Year 2018 After Market Close on December 11, 2017
TUSTIN, Calif. , Dec. 04, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company focused on helping improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that it will
View HTML
Toggle Summary Peregrine Pharmaceuticals, Ronin Trading and SW Investment Management Announce Settlement Agreement
Peregrine Board Reconstituted with Four New Independent Directors
View HTML
Toggle Summary Peregrine Announces Date of 2017 Annual Meeting of Stockholders
TUSTIN, Calif. , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP) today announced that its 2017 Annual Meeting of Stockholders will be held on January 18, 2018 , at 14191 Myford Road , Tustin, California 92780, located within the company's manufacturing
View HTML
Toggle Summary Peregrine Pharmaceuticals Announces Appointment of Patrick Walsh to Board of Directors of Peregrine and Avid Bioservices
Industry Veteran with More Than Thirty Years of Experience Leading Successful Contract Development and Pharmaceutical Manufacturing Organizations
View HTML
Toggle Summary Peregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid Bioservices
Senior Executive with Thirty Years of Biologics Experience including Contract Development and Manufacturing Organization (CDMO) Leadership
View HTML
Toggle Summary Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent Developments
             -- Avid Bioservices Records Revenues of $27 Million in the First Quarter of FY2018 -- -- Roger Lias , Ph.D., Appointed President of Avid Bioservices as Company Continues Transition to a CDMO Focused Business -- -- Supported by Recent Positive Data, Company is Pursuing Strategic Options
View HTML
Toggle Summary Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid Bioservices
Senior Executive with More Than Two Decades of CDMO Management Experience to Also Join Peregrine's Board of Directors
View HTML
Toggle Summary Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed Glioblastoma
Trial is First of Three Planned Bavituximab Combination Studies Being Conducted as Part of Collaboration with National Comprehensive Cancer Network® (NCCN®)
View HTML
Toggle Summary Peregrine to Report Financial Results for First Quarter of Fiscal Year 2018 After Market Close on September 11, 2017
TUSTIN, Calif. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D
View HTML